Get the Stockscreener App
9.09
3.50%
-0.33
After Hours:
9.45
0.36
+3.96%
Corvus Pharmaceuticals Inc Stock (CRVS) Latest News
Connor Clark & Lunn Investment Management Ltd. Has $724,000 Stock Position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) - MarketBeat
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
FY2024 EPS Estimates for CRVS Cut by Cantor Fitzgerald - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Sees Large Volume IncreaseWhat's Next? - MarketBeat
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2024 Earnings Call Transcript - MSN
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Shares Sold by Towerview LLC - MarketBeat
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis - The Manila Times
Corvus drug shows promise in systemic sclerosis models - Investing.com
Corvus' Soquelitinib Shows Promise in Preventing Systemic Sclerosis Lung Damage in Key Study | CRVS Stock News - StockTitan
Corvus Pharmaceuticals target raised to $13 by Jefferies - Investing.com UK
Corvus Pharmaceuticals: The Market Likes The Story (NASDAQ:CRVS) - Seeking Alpha
Earnings call: Corvus Pharmaceuticals reports Q3 financials and trial updates - Investing.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Given New $14.00 Price Target at Oppenheimer - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Shares Gap Up Following Analyst Upgrade - MarketBeat
Corvus Pharmaceuticals Inc (CRVS) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid ... By GuruFocus - Investing.com Canada
Corvus Pharmaceuticals Reports Q3 2024 Financial Results - TipRanks
Corvus: Q3 Earnings Snapshot - San Antonio Express-News
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results - The Manila Times
Corvus Pharma Reports $41.7M Cash Position, Advances Key Clinical Trials Despite Q3 Loss | CRVS Stock News - StockTitan
Corvus Pharmaceuticals (NASDAQ:CRVS) Hits New 1-Year HighHere's Why - MarketBeat
Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer - The Manila Times
Corvus' Ciforadenant Shows Promise in Prostate Cancer Treatment, Doubles Response Rate | CRVS Stock News - StockTitan
Palantir Technologies Inc Cl A (PLTR-N) QuotePress Release - The Globe and Mail
Corvus Pharmaceuticals (CRVS) Scheduled to Post Earnings on Tuesday - MarketBeat
Corvus Pharmaceuticals stock soars to 52-week high of $9.69 - Investing.com
Sunrun Inc (RUN-Q) QuotePress Release - The Globe and Mail
Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail
T-Cell Lymphoma Pipeline Insight Analysis Report 2024 - GlobeNewswire Inc.
Godaddy Inc (GDDY-N) QuotePress Release - The Globe and Mail
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024 - The Manila Times
Enersys Inc (ENS-N) QuotePress Release - The Globe and Mail
Corvus Pharmaceuticals (NASDAQ:CRVS) Reaches New 1-Year HighStill a Buy? - MarketBeat
Amer Superconductor (AMSC-Q) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Toll Brothers Inc (TOL-N) QuotePress Release - The Globe and Mail
Corvus Pharmaceuticals (NASDAQ:CRVS) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
United Parcel Service (UPS-N) QuotePress Release - The Globe and Mail
S&P GSCI (GDF25) Quote - The Globe and Mail
Lumber Physical (LBU23) Quote - The Globe and Mail
Corvus Pharmaceuticals (NASDAQ:CRVS) Lowered to "Sell" Rating by StockNews.com - MarketBeat
Corvus Pharmaceuticals stock soars to 52-week high of $8.74 By Investing.com - Investing.com Canada
Corvus Pharmaceuticals stock soars to 52-week high of $8.74 - Investing.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Hits New 12-Month HighHere's What Happened - MarketBeat
Where are the Opportunities in (CRVS) - Stock Traders Daily
Msc Industrial Direct Company (MSM-N) QuotePress Release - The Globe and Mail
Insiders Rewarded With US$3.9m Addition To Investment As Corvus Pharmaceuticals Stock Hits US$480m - Simply Wall St
Corvus Pharmaceuticals (NASDAQ:CRVS) Trading Up 6%Here's Why - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Rating Upgraded by Mizuho - MarketBeat
Corvus Pharmaceuticals (NASDAQ:CRVS) Lifted to "Hold" at StockNews.com - MarketBeat
Corvus Pharmaceuticals secures new South San Francisco lease - Investing.com
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):